Anika Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 10.50
Dividend & YieldN/A$ (N/A)
Beta 0.96
Market capitalization 430.4M
Operating cash flow 8.4M
ESG Scores unknown

Company description

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Sector: Healthcare - Industry: Medical Devices

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -1.67M 767k 822k -1.1M
Total Cashflows From Investing Activities -50.26M 39.69M -71.26M -3.12M
Net Borrowings -558k -558k -558k -201k
Total Cash From Financing Activities -28.9M -8.14M -3.77M -6.78M
Change To Operating Activities 2.21M 1.1M -3.89M 528k
Issuance Of Stock 2.89M 22.15M 1.52M 1.13M
Net Income 18.72M 27.19M -23.98M 4.13M
Change In Cash -44.21M 68.42M -61.65M -1.43M
Effect Of Exchange Rate 29k -133k 327k 69k
Total Cash From Operating Activities 34.92M 37.01M 13.06M 8.4M
Depreciation 5.91M 5.99M 13.46M 14.32M
Change To Account Receivables 2.91M -1.84M 5.86M -6.22M
Other Cashflows From Financing Activities -4.48M -4.48M -4.48M -7.22M
Change To Netincome 13.49M 10.46M 37.04M 4.66M
Capital Expenditures -4.66M -2.83M -1.63M -5.14M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 18.19M 16.66M 22.02M 26.73M
Income Before Tax 23.21M 36.12M -28.62M 2.43M
Net Income 18.72M 27.19M -23.98M 4.13M
Selling General Administrative 28.14M 34.56M 56.74M 74.1M
Gross Profit 74.28M 85.86M 82.03M 91.85M
Ebit 27.95M 34.64M 3.27M -8.97M
Operating Income 27.95M 34.64M 3.27M -8.97M
Interest Expense -302k -302k -302k -188k
Income Tax Expense 4.49M 8.93M -4.64M -1.71M
Total Revenue 105.56M 114.61M 130.46M 147.79M
Cost Of Revenue 31.28M 28.75M 48.43M 55.94M
Total Other Income ExpenseNet -4.74M 1.48M -31.9M 11.4M
Net Income From Continuing Ops 18.72M 27.19M -23.98M 4.13M
Net Income Applicable To Common Shares 18.72M 27.19M -23.98M 4.13M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 15.38M 42.33M 93.2M 60.45M
Total Stockholder Equity 263.61M 288.38M 272.4M 287.08M
Other Current Liabilities 785k 13.09M 4.32M
Total Assets 278.99M 330.71M 365.61M 347.54M
Common Stock 142k 143k 143k 144k
Other Current Assets
Retained Earnings 218.23M 245.43M 221.44M 225.58M
Treasury Stock -5.53M -5.9M -4.54M -5.72M
Cash 89.04M 157.46M 95.82M 94.39M
Total Current Liabilities 11.29M 16.28M 36.87M 29.8M
Other Stockholder Equity -5.53M -5.9M -4.54M -5.72M
Property, Plant, and Equipment 54.11M 73.65M 73.23M 68.56M
Total Current Assets 202.94M 234.31M 177.38M 168.53M
Net Tangible Assets 246.57M 273.1M 172.83M 196.92M
Net Receivables 20.77M 23.08M 24.1M 29.84M
Accounts Payable 3.14M 3.83M 8.98M 7.63M


Insider Transactions

Here are the insider transactions of stock shares related to Anika Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
LEVITZ MICHAEL L.D2022-08-10Chief Financial Officer3.86k
HENNEMAN JOHN BELL IIIStock Award(Grant) at price 0.00 per share.D2022-06-08Director7.95k
VOGT SUSAN L NStock Award(Grant) at price 0.00 per share.D2022-06-08Director7.95k
CONLEY SHERYL LStock Award(Grant) at price 0.00 per share.D2022-06-08Director7.95k
THOMPSON JEFFERY S.Stock Award(Grant) at price 0.00 per share.D2022-06-08Director7.95k
LARSEN GLENN RStock Award(Grant) at price 0.00 per share.D2022-06-08Director7.95k
RICHARD STEPHENStock Award(Grant) at price 0.00 per share.D2022-06-08Director7.95k
COLLERAN DAVID B J.D.Purchase at price 21.37 per share.D2022-05-11General Counsel1.5k
BLANCHARD CHERYL RD2022-04-26Chief Executive Officer24.58k
COLLERAN DAVID B J.D.Purchase at price 26.65 per share.D2022-03-14General Counsel1.5k
BLANCHARD CHERYL RPurchase at price 25.36 - 25.81 per share.D2022-03-11Chief Executive Officer8.1k
LEVITZ MICHAEL L.Purchase at price 24.62 per share.D2022-03-11Chief Financial Officer4k
THOMPSON JEFFERY S.Purchase at price 24.66 per share.D2022-03-11Director2k
BLANCHARD CHERYL RD2022-03-09Chief Executive Officer14.42k
LEVITZ MICHAEL L.D2022-03-09Chief Financial Officer4.44k
COLLERAN DAVID B J.D.D2022-03-09General Counsel3.68k
FINNERTY THOMASD2022-03-09Officer2.55k
COLLERAN DAVID B J.D.D2022-03-04General Counsel2.5k
FINNERTY THOMASD2022-02-25Officer5.83k
FINNERTY THOMASStock Award(Grant) at price 0.00 per share.D2022-02-09Officer10.12k
CONLEY SHERYL LStock Award(Grant) at price 0.00 per share.D2021-10-28Director8.18k
LEVITZ MICHAEL L.Purchase at price 40.20 - 40.21 per share.D2021-08-12Chief Financial Officer3.63k
LEVITZ MICHAEL L.D2021-08-10Chief Financial Officer3.86k
LOEROP JAMESD2021-07-08Officer3k
LAND RAYMOND JStock Award(Grant) at price 0.00 per share.D2021-06-16Director4.17k
HENNEMAN JOHN BELL IIIStock Award(Grant) at price 0.00 per share.D2021-06-16Director4.17k
VOGT SUSAN L NStock Award(Grant) at price 0.00 per share.D2021-06-16Director4.17k
THOMPSON JEFFERY S.Stock Award(Grant) at price 0.00 per share.D2021-06-16Director4.17k
LARSEN GLENN RStock Award(Grant) at price 0.00 per share.D2021-06-16Director4.17k
RICHARD STEPHENStock Award(Grant) at price 0.00 per share.D2021-06-16Director4.17k
BLANCHARD CHERYL RConversion of Exercise of derivative security at price 33.40 per share.D2021-06-15Chief Executive Officer2.99k
HENNEMAN JOHN BELL IIIPurchase at price 42.86 per share.D2021-05-18Director2k
LAND RAYMOND JSale at price 42.60 per share.D2021-05-12Director2k
BLANCHARD CHERYL RD2021-04-26Chief Executive Officer24.57k
COLLERAN DAVID B J.D.D2021-03-04General Counsel2.5k
FINNERTY THOMASD2021-02-26Officer5.83k
LOEROP JAMESD2021-02-25Officer1.57k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Anika Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Anika Therapeutics Inc

Here is the result of two systematic investment strategies applied to Anika Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Anika Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Anika Therapeutics Inc:

Anika Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 14.42% on the backtest period.

Performance at glance

Performance

14.42 %

Latent gain

249.65 $

Invested capital

1731.67 $

Annualized return

3.52 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Anika Therapeutics Inc

This is the result of two momentum investment strategies applied to Anika Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Anika Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Anika Therapeutics Inc:

Anika Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 23.59% of return on Anika Therapeutics Inc. That represents 1117.43$ of latent gain with 4736.47$ of employed capital.
  • The second momentum investment strategy would give 27.93% of return on Anika Therapeutics Inc. That represents 894.75$ of latent gain with 3202.98$ of employed capital.
Performance at glance (1Q Momentum)

Performance

23.59 %

Latent gain

1117.43 $

Invested capital

4736.47 $

Annualized return

-4.56 %
Performance at glance (2Q Momentum)

Performance

27.93 %

Latent gain

894.75 $

Invested capital

3202.98 $

Annualized return

7.72 %

Momentum equity curve on Anika Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Anika Therapeutics Inc:

Anika Therapeutics Inc momentum equity

Note: the dividends potentially given by Anika Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Anika Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Anika Therapeutics Inc since the beginning:

Anika Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Anika Therapeutics Inc

Buy the dip entry openings on Anika Therapeutics Inc

Anika Therapeutics Inc

The performance achieved by the robo-advisor on Anika Therapeutics Inc is -9.58%. That represents -23.85$ of latent gain with 249.0$ of employed capital. The following chart shows Anika Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Anika Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-9.58 %

Latent gain

-23.85 $

Invested capital

249.0 $

Annualized return

-4.56 %

Equity curve of the strategy applied to Anika Therapeutics Inc

The following chart shows the result of the investment strategy applied to Anika Therapeutics Inc:

Anika Therapeutics Inc

Note: the dividends potentially given by Anika Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Anika Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Anika Therapeutics Inc:

Anika Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Anika Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Anika Therapeutics Inc.

Equity curve comparison on Anika Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Anika Therapeutics Inc investment strategy comparison

Employed capital comparison on Anika Therapeutics Inc

Anika Therapeutics Inc investment comparison

Performance comparison on Anika Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 14.42% 249.65$ 1731.67$ 3.52%
Momentum 1 quarter 23.59% 1117.43$ 4736.47$ 6.11%
Momentum 2 quarters 27.93% 894.75$ 3202.98$ 7.72%
Non-directional -9.58% -23.85$ 249.0$ -4.56%
Annualized return comparison

Automatic investment

3.52 %

Momentum 1Q

7.72 %

Momentum 2Q

7.72 %

Non-directional

-4.56 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Anika Therapeutics Inc:

Note: The algorithm computes the probability of correlation between Anika Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Anika Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Anika Therapeutics Inc
Country United States
City Bedford
Address 32 Wiggins Avenue
Phone 781 457 9000
Website www.anikatherapeutics.com
FullTime employees 297
Industry Medical Devices
Sector Healthcare
Exchange XNAS
Ticker ANIK
Market www.nasdaq.com

Anika Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown